Bio-Path Holdings, Inc.
BPTH · OTC
Bulios Fair Price
$0
100.0% downside
Current Price
$0.0001
According to Bulios Fair Price, BPTH is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Bio-Path Holdings, Inc. (BPTH) is a biopharmaceutical company focused on developing drug candidates for the treatment of various types of cancer. Its main therapeutic platform includes liposomal delivery technology, which enables targeted delivery of therapeutic agents directly to cancer cells. The company primarily focuses on treating leukemia and various types of carcinomas, including breast, pancreatic, and lung cancers. Bio-Path Holdings conducts clinical trials and research to assess the efficacy of its drug candidates and their potential therapeutic benefits. Shares of Bio-Path Holdings, Inc. (BPTH) may be suitable for investors seeking opportunities in the biotechnology sector with a focus on innovative approaches to combating cancer.
Sector
Healthcare
Industry
Biotechnology
CEO
Vikram Paul Grover
Employees
1
Headquarters
Bellaire
Upcoming events
Earnings
Upcoming earnings report